Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Other Operating Expenses (2018 - 2025)

Outlook Therapeutics (OTLK) has disclosed Other Operating Expenses for 4 consecutive years, with -$46.2 million as the latest value for Q3 2025.

  • Quarterly Other Operating Expenses changed N/A to -$46.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$46.2 million through Dec 2025, down 8859.68% year-over-year, with the annual reading at -$70.2 million for FY2025, 3.18% down from the prior year.
  • Other Operating Expenses for Q3 2025 was -$46.2 million at Outlook Therapeutics, down from $104296.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was -$46.2 million in Q3 2025, with the low at -$46.2 million in Q3 2025.